Recombinant Human HPRG Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 1869-HP
Key Product Details
Product Specifications
Source
Val19-Lys525, with a C-terminal 10-His tag
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
When 1 x 105 cells/well are added to Recombinant Human HPRG coated plates, adhesion is induced in a dose-dependent manner in the presence of Concanvalin A. The ED50 for this effect is 0.4-2 μg/mL.
Formulation, Preparation and Storage
1869-HP
Formulation | Lyophilized from a 0.2 μm filtered solution in Tris-Citrate and NaCl. |
Reconstitution |
Reconstitute at 100 μg/mL in sterile PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: HPRG
Human histidine-rich glycoprotein (HPRG) is a multidomain, monomeric, secreted, 67-75 kDa member of the cystatin superfamily of molecules (1, 2). Its name derives from the fact that 26% of its amino acids (aa) are histidine and proline. In human, it is synthesized as a 525 aa precursor that contains an 18 aa signal sequence and a 507 aa mature region (3). Five distinct domains are recognized in the mature molecule. There are two N-terminal cystatin-like modules (aa 19-254) and one His-Pro-rich region (aa 350-497) that is flanked by two Pro-rich segments (aa 276-321 and 498-525) (3, 4). The His-Pro-rich region contains 10 tandem repeats with an HHPHG motif, and the N- and C-termini are linked by a disulfide bond (3, 5, 6). Human HPRG is only 60% aa identical to mouse HPRG. There are multiple ligands for HPRG. These include small molecular weight molecules (metal ions; heme), hemostatic molecules (heparan sulfate; TSP; plasminogen), and immune system components (T cells; macrophages) (1, 5). About 50% of plasma plasminogen circulates bound to HPRG. Upon immobilization to cell surface tropomyosin in a Zn++‑dependent manner, it is converted to plasmin by tPA (7-9). HPRG also shows antiangiogenic activity on endothelial cells (10).
References
- Jones, A.L. et al. (2005) Immunol. Cell Biol. 83:106.
- Koide, T. and S. Odani (1987) FEBS Lett. 216:17.
- Koide, T. et al. (1986) Biochemistry 25:2220.
- SwissProt Accession # P04196.
- Borza, D-B. et al. (1996) Biochemistry 35:1925.
- Sorensen, C.B. et al. (1993) FEBS Lett. 328:285.
- Donate, F. et al. (2004) Cancer Res. 64:5812.
- Borza, D-B. and W.T. Morgan (1997) J. Biol. Chem. 272:5718.
- Guan, X. et al. (2004) Thromb. Haemost. 92:403.
- Juarez, J.C. et al. (2002) Cancer Res. 62:5344.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional HPRG Products
Product Documents for Recombinant Human HPRG Protein, CF
Product Specific Notices for Recombinant Human HPRG Protein, CF
For research use only